902152-76-5

Usage

Uses

Used in Pharmaceutical Industry:
(S)-3-Amino-1-methyl-piperidine is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to facilitate the creation of complex molecular structures. Its structural versatility allows for the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, (S)-3-Amino-1-methyl-piperidine is utilized as a versatile building block for the production of a wide range of organic compounds. Its compatibility with numerous chemical reactions enables the synthesis of diverse molecules with potential applications in various industries.
Used in Drug Development:
(S)-3-Amino-1-methyl-piperidine is employed as a crucial component in drug development, where its unique structural properties contribute to the design and synthesis of novel biologically active molecules. (S)-3-Amino-1-methyl-piperidine plays a significant role in advancing the discovery and creation of new therapeutic agents.

Upstream product

• 625471-18-3 tert-butyl (3S)-3-aminopiperidine-1-carboxylate 
• 902152-77-6 (S)-tert-butyl (1-methylpiperidin-3-yl)carbamate 

Downstream Products

• 912369-04-1 4-{[(3S)-1-methylpiperidin-3-yl]amino}-2-phenylthieno[3,2-c]pyridine-7-carbonitrile 
• 1201495-72-8 1-(3-fluorophenyl)-4-ureido-1H-pyrrole-3-carboxylic acid ((S)-1-methyl-piperidin-3-yl)-amide 

Relevant academic research and scientific papers

Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors

Checkpoint kinase 1 (CHK1) inhibitors are potential cancer therapeutics that can be utilized for enhancing the efficacy of DNA damaging agents. Multiple small molecule CHK1 inhibitors from different chemical scaffolds have been developed and evaluated in clinical trials in combination with chemotherapeutics and radiation treatment. Scaffold morphing of thiophene carboxamide ureas (TCUs), such as AZD7762 (1) and a related series of triazoloquinolines (TZQs), led to the identification of fused-ring bicyclic CHK1 inhibitors, 7-carboxamide thienopyridines (7-CTPs), and 7-carboxamide indoles. X-ray crystal structures reveal a key intramolecular noncovalent sulfur-oxygen interaction in aligning the hinge-binding carboxamide group to the thienopyridine core in a coplanar fashion. An intramolecular hydrogen bond to an indole NH was also effective in locking the carboxamide in the preferred bound conformation to CHK1. Optimization on the 7-CTP series resulted in the identification of lead compound 44, which displayed respectable drug-like properties and good in vitro and in vivo potency.

TROPANE COMPOUNDS

A compound according to Formula I or II: (I) or (II) wherein R1, R1b, R2, L1, and L2 and L2b are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.

SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS

This invention relates to novel compounds of Formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds possess CHK1 kinase inhibitory activity, PDK1 inhibitory activity and Pak kinase inhibitory activity and are accordingly useful in the treatment and/or prophylaxis of cancer.

PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S

The invention provides compounds of the formula (I), or salts, tautomers, N-oxides or solvates thereof wherein: R1 is selected from: (a) 2,6-dichlorophenyl; (b) 2,6-difluorophenyl; (c) a 2,3,6-trisubstituted phenyl group wherein the substituents for the phenyl group are selected from fluorine, chlorine, methyl and methoxy; (d) a group R0; (e) a group R a; (f) a group Rlb; (g) a group Rlc; (h) a group Rld; and 0) 2,6-difluorophenylamino ; wherein R )0υ, r R> llaa, T Rj I1bD, T R) I1cC, r R> Iidα, r R?2zaa, r R>22bD and RJ are as defined in the claims. The compounds have activity as inhibitors of cdk kinase (such as cdkl or cdk2) and glycogen synthase kinase-3 activity.